English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Resistance threatens all our currently available anti-malarial drugs. Triple artemisinin-containing combination anti-malarial treatments (TACTs) combine an artemisinin derivative with two slowly eliminated partner drugs. TACTs are undergoing large-scale trials. If they prove safe, well-tolerated and efficacious then they should be deployed. This is in order to protect and extend the useful therapeutic life of the current generation of anti-malarial drugs, which are so essential for malaria control and elimination.

Triple artemisinin-containing combination anti-malarial treatments should be implemented now to delay the emergence of resistance